<DOC>
	<DOCNO>NCT00272688</DOCNO>
	<brief_summary>An open , observational health economic study estimate marginal cost health consequence replace conventional Parkinsons disease therapy intraduodenal levodopa administer continuously</brief_summary>
	<brief_title>Continuous Delivery Levodopa Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Clinical diagnosis idiopathic Parkinsons disease Motor fluctuation despite optimised per oral treatment Severe dementia , confusion , psychosis depression Patients contraindication levodopa treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>